Nektar Therapeutics (NKTR) earnings
Quarterly results of Nektar Therapeutics as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Next earnings date
Nektar Therapeutics was expected to report around November 5, 2026; nothing is on file with the SEC yet.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Nektar Therapeutics reported revenue of $10.1M (-9.3% on the same quarter a year earlier) and a net loss of $40.6M.
Diluted earnings per share were -$1.23.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $10.1M | -9.3% | -$40.6M | -$1.23 |
| Q1 FY2026 | $10.9M | +3.8% | -$44.9M | -$1.82 |
| Q4 FY2025 | $21.8M | -25.3% | -$36.1M | - |
| Q3 FY2025 | $11.8M | -51.1% | -$35.5M | -$1.87 |
| Q2 FY2025 | $11.2M | - | -$41.6M | -$2.95 |
| Q1 FY2025 | $10.5M | - | -$50.9M | -$3.62 |
| Q4 FY2024 | $29.2M | - | $7.3M | - |
| Q3 FY2024 | $24.1M | - | -$37.1M | -$2.66 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
- Quarterly report 10-Q
- Quarterly results 8-K
When is Nektar Therapeutics's next earnings date?
Nektar Therapeutics was expected to report around November 5, 2026; nothing is on file with the SEC yet.
What were Nektar Therapeutics's latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Nektar Therapeutics reported revenue of $10.1M and a net loss of $40.6M. The figures come from its filing with the SEC.
Is Nektar Therapeutics's revenue growing?
Revenue in Q2 FY2026 was $10.1M, down 9.3% from $11.2M in the same quarter a year earlier.
Get an email when NKTR reports
Follow NKTR and we email you its next results the day they are filed, with the numbers explained.